Everest Medicines Hits Profitability Milestone with 157% Revenue Surge
Event summary
- Everest Medicines reported a 157.3% year-on-year revenue increase to RMB 1,147.8 million for H1 2026, achieving non-IFRS net profit of RMB 97.2 million.
- Gross margin excluding non-cash items reached 73.7%, with operating expenses as a percentage of revenue decreasing by 64.0 percentage points year-on-year.
- The company received RMB 770 million in July 2026 from an upfront payment under its global licensing agreement for civorebrutinib.
- Key commercial products NEFECON®, VELSIPITY®, and XERAVA® drove sales growth, supported by expanded market access and localized manufacturing.
- Everest Medicines advanced its proprietary AI+mRNA platform, with EVM16 achieving first-in-human clinical data readout and EVM18 progressing toward global IND filings.
The big picture
Everest Medicines' strong H1 2026 results reflect its strategic shift toward innovation-driven growth and global expansion. The company's ability to achieve profitability while expanding its pipeline and commercial footprint underscores its positioning in the competitive biopharmaceutical landscape. With a focus on integrating global innovation resources and strengthening end-to-end capabilities, Everest Medicines is poised to capitalize on unmet medical needs across cardiovascular, kidney, metabolic, autoimmune, ophthalmology, and critical care therapeutic areas.
What we're watching
- Pipeline Execution
- The pace at which Everest Medicines advances its diverse pipeline, including CARDAMYST®, LEROCHOL®, and MT1013, will determine its ability to sustain growth momentum.
- Global Expansion
- How effectively Everest Medicines scales its pan-Asia-Pacific commercialization platform will impact its market penetration and revenue diversification.
- Innovation Investment
- Whether the company's continued investment in AI+mRNA platforms and in vivo CAR-T therapies will yield breakthrough therapies and maintain its competitive edge.